TW202300530A - 一種抗egfr/vegf雙功能融合蛋白及其用途 - Google Patents

一種抗egfr/vegf雙功能融合蛋白及其用途 Download PDF

Info

Publication number
TW202300530A
TW202300530A TW111115786A TW111115786A TW202300530A TW 202300530 A TW202300530 A TW 202300530A TW 111115786 A TW111115786 A TW 111115786A TW 111115786 A TW111115786 A TW 111115786A TW 202300530 A TW202300530 A TW 202300530A
Authority
TW
Taiwan
Prior art keywords
egfr
fusion protein
vegf
seq
acid sequence
Prior art date
Application number
TW111115786A
Other languages
English (en)
Chinese (zh)
Inventor
鄧嵐
黃浩旻
禎平 朱
Original Assignee
大陸商丹生醫藥技術(上海)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商丹生醫藥技術(上海)有限公司 filed Critical 大陸商丹生醫藥技術(上海)有限公司
Publication of TW202300530A publication Critical patent/TW202300530A/zh

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
TW111115786A 2021-04-27 2022-04-26 一種抗egfr/vegf雙功能融合蛋白及其用途 TW202300530A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110458717.0 2021-04-27
CN202110458717.0A CN115246886A (zh) 2021-04-27 2021-04-27 一种抗egfr/vegf双功能融合蛋白及其用途

Publications (1)

Publication Number Publication Date
TW202300530A true TW202300530A (zh) 2023-01-01

Family

ID=83695778

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111115786A TW202300530A (zh) 2021-04-27 2022-04-26 一種抗egfr/vegf雙功能融合蛋白及其用途

Country Status (3)

Country Link
CN (2) CN115246886A (fr)
TW (1) TW202300530A (fr)
WO (1) WO2022228424A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102633883B (zh) * 2012-02-24 2014-06-25 上海白泽生物科技有限公司 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途
WO2017186950A1 (fr) * 2016-04-28 2017-11-02 Biomunex Pharmaceuticals Anticorps bispécifiques ciblant l'egfr et her2
EP3668893A4 (fr) * 2017-08-16 2021-08-04 Dragonfly Therapeutics, Inc. Protéines se liant à nkg2d, cd16 et à l'egfr, hla-e, ccr4, ou pd-l1
CN110835375B (zh) * 2018-08-16 2021-04-06 上海洛启生物医药技术有限公司 一种抗pd-1/egfr双特异性抗体及其用途
CN112552410A (zh) * 2019-09-26 2021-03-26 三生国健药业(上海)股份有限公司 一种抗体融合蛋白及其制法和在抗肿瘤中的应用

Also Published As

Publication number Publication date
WO2022228424A1 (fr) 2022-11-03
CN115246886A (zh) 2022-10-28
CN117242097A (zh) 2023-12-15

Similar Documents

Publication Publication Date Title
JP7256580B2 (ja) 結合剤
JP7336122B2 (ja) 抗vegf単一ドメイン抗体およびその応用
WO2020043184A1 (fr) Anticorps bifonctionnel anti-pd-1 et anti-vegfa, composition pharmaceutique et utilisation associées
CN110462038A (zh) 抗gprc5d抗体和包含所述抗体的分子
KR20110047698A (ko) c-Met에 특이적으로 결합하는 항체 및 그의 용도
US20220356246A1 (en) Anti-ROR1 antibodies and preparation method and uses thereof
JP6644956B2 (ja) Vegfに対する合成の抗体およびそれらの使用
EP4209513A1 (fr) Anticorps bispécifique anti-vegf-anti-pd-l1, composition pharmaceutique de celui-ci et utilisations associées
US20230071422A1 (en) ANTI-CD3 and ANTI-CD123 Bispecific Antibody and Use Thereof
JP2022514693A (ja) Muc18に特異的な抗体
CN110922486B (zh) 一种分离的结合抗原psma的蛋白及其用途
JP2022514786A (ja) Muc18に特異的な抗体
KR20210063782A (ko) c-kit에 대한 항체 및 이의 용도
WO2022068894A1 (fr) Molécule bifonctionnelle ciblant simultanément pd-l1 et vegf et son utilisation médicale
JP2024514855A (ja) Dll3に対する結合分子及びその使用
WO2021244554A1 (fr) Anticorps bispécifique anti-pdl1 × egfr
WO2021047386A1 (fr) Nano-anticorps ciblant l'antigène caix et son application
CN111303288B (zh) 一种分离的结合抗原psma的蛋白及其用途
WO2022228424A1 (fr) Protéine de fusion bifonctionnelle anti-egfr/vegf et son utilisation
CN110563847A (zh) 用于治疗性用途的免疫检查点抑制剂
WO2023041065A1 (fr) Anticorps ciblant ceacam5/6 humain, procédé de préparation et application
CN111840571B (zh) 一种抗体药物偶联物及其用途
CN114539415B (zh) 一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途
WO2021244587A1 (fr) Protéine de fusion anti-pd-l1/tgf-ss
EP4223777A1 (fr) Anticorps anti-cd3 et ses utilisations